HIND: Vyome Therapeutics Price to Sales

Vyome Holdings Inc delegates clinical testing and product manufacturing to external contractors, creating a heavy reliance on vendors. The P/S multiple trend on GURU.Markets visualizes this process, with the current metric standing at 72.70. The company is also implementing minimally invasive obesity treatments in collaboration with clinics, while simultaneously modernizing its facilities to scale immunotherapy production in the future.
Metric breakdowns and analytics for reshapelifesciences.com (HIND)

The P/S ratio determines the market value of a unit of revenue, allowing for the identification of fair business valuation boundaries through the analysis of price corridors and export potential. By analyzing the divergence of the P/S from its historical average, an investor assesses whether the asset is overbought, taking into account the impact of Vyome Holdings Inc. (HIND) strict ESG standards regarding chemical waste disposal on the company's long-term capitalization.